GlassScriptPhysician profile
Shabier A Raffee
NPI 1962661975
$4,009.43
in general payments reported to CMS, 2019-2025
22 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $373 · 2021: $547 · 2022: $528 · 2023: $688 · 2024: $962 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $700.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $612.47 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $543.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $429.36 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $374.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $286.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $277.94 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $167.83 | 2021-2023 | |
| Allergan, INC. | $139.50 | 2019 | |
| Ucb, INC. | $74.41 | 2024 | Nayzilam |
| Nestle Healthcare Nutrition INC. | $64.58 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.91 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $52.96 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $47.55 | 2020 | |
| Abbvie INC. | $38.86 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $24.33 | 2019-2021 | |
| Eisai INC. | $22.01 | 2023 | |
| Amgen INC. | $21.21 | 2024 | Repatha |
| Sunovion Pharmaceuticals INC. | $20.51 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.95 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.35 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabier Raffee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.